Laddar...
A Novel Hydrogen Sulfide Prodrug, SG1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients
Recent studies demonstrate robust molecular cross talk and signaling between hydrogen sulfide (H(2)S) and nitric oxide (NO). Heart failure (HF) patients are deficient in both H(2)S and NO, two molecules that are critical for cardiovascular homeostasis. A phase I clinical trial of a novel H(2)S prodr...
Sparad:
| I publikationen: | Cardiovasc Ther |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
John Wiley and Sons Inc.
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5034803/ https://ncbi.nlm.nih.gov/pubmed/25930144 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1755-5922.12128 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|